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COHE physicians who more often adopted occupational health best practices
had 57% fewer disability days (p  0.001) compared with patients treated by
COHE physicians who less frequently adopted best practices. CONCLUSIONS:
Physician financial incentives, coupled with care management support, can im-
prove outcomes and reduce costs for patients receiving occupational health care.
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OBJECTIVES: Kyphosis due at least one vertebral compression fracture (VCF) is
prevalent among osteoporotic patients, resulting in well documented symptoms
and impact on functioning and well-being. Assessing health outcomes of interven-
tions concentrates on consequences of back pain, omitting relevant aspects of
increased morbidity. A three-part study led to development of a conceptual mea-
surement framework for comprehensive assessment of symptoms, impact and
treatment benefits in kyphosis. METHODS: We developed a literature-based
(PubMed, Medline) Disease Model (DM) for kyphosis for selecting and developing
outcome measures, as recommended by regulatory agencies. In-depth interviews
were conducted among patients (n10) and physicians (n10) to test the DM.
Physician respondents were PCPs or specialists currently treating patients with
osteoporotic kyphosis. Patient respondents were 50 years old with an osteopo-
rotic VCF 90 days prior. Relevant Patient-Reported Outcome instruments (PROs)
were evaluated for appropriateness in this population. RESULTS: The DM included
signs, symptoms, causes/triggers, exacerbations, and functional/well-being im-
pact of kyphosis. The DM content was largely confirmed by all respondents, how-
ever patients offered new concepts of emotional and functional impact and clini-
cians discounted psychosocial concepts (well-being and sleep impairment) and
added clinical evaluations of the spinal deformity. Related to these findings, PRO
instruments lacked adequate content validity or measurement properties for eval-
uating kyphosis outcomes. Close matches were the IOF Quality of Life question-
naire (Qualeffo-41) and the Osteoporosis Assessment Questionnaire (OPAQ),
though neither includes gastrointestinal or respiratory symptoms. CONCLUSIONS:
This study confirms the need for more comprehensive assessment of health out-
comes in kyphosis, because current approaches omit key concepts (gastrointesti-
nal and respiratory symptoms) and functional impact being a major cost-driver. A
comprehensive evaluation of the severity and impact of kyphosis requires clinician
evaluation of spinal deformity and patient-report of symptoms (spinal, respiratory,
GI) and functional impact and a more complete understanding of the unique infor-
mation provided by different measurements.
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OBJECTIVES: To compare the clinical effectiveness of abatacept and other biologic
Disease Modifying Anti-Rheumatic Drugs (DMARDs), as measured by Health As-
sessment Questionnaire (HAQ) score, in patients with rheumatoid arthritis (RA)
who have responded inadequately to methotrexate (MTX-IR) in the UK
environment.METHODS:A systematic literature review (conducted in line with UK
reimbursement environment) identified controlled trials investigating the efficacy
of abatacept (3 studies), adalimumab (2), certolizumab pegol (2), etanercept (2),
golimumab(1) and infliximab(2) in MTX-IR patients. The identified trials were com-
parable in design, included patients, and concomitant treatment (MTX). Mixed
treatment comparison analyses were performed on HAQ change from baseline
(CFB) at 24 and 52 weeks. Results were expressed as difference in HAQ CFB score
between treatments and expected HAQ CFB and the 95% Credible Interval (CrI) per
treatment at 24 and 52 weeks. RESULTS: The analysis of HAQ CFB at 24 weeks
showed that abatacept/MTX is more efficacious than MTX monotherapy (0.30,
95%CrI:0.42,,0.16) and shows small numeric differences versus other biologics/
MTX (range:0.11 to 0.9). The expected mean HAQ CFB at 24 weeks for abatacept
(0.57) was superior to placebo (0.27) and comparable to all the alternative treat-
ments (adjusted mean between 0.46 and 0.65). The findings at 52 weeks are in
line with those at 24-weeks, although no data was available for golimumab. Sce-
nario analyses confirmed the robustness of the findings. CONCLUSIONS: Abata-
cept in combination with MTX is expected to result in a comparable improvement
in functional status as measured in HAQ score and ACR responses as other biologic
agents in MTX-IR RA patients.
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OBJECTIVES: Both intramuscular interferon (IM IFN) -1a and fingolimod slow re-
duce progression and relapses among patients with multiple sclerosis (MS). In a
head-to-head trial, fingolimod demonstrated greater reductions in relapses, but no
difference in progression, compared to IM IFN--1a; fingolimod-treated patients
were at increased risk of some unintended treatment effects, however. Whether
the difference in efficacy between fingolimod and IM IFN--1a is offset by the
increased risk of unintended effects is unknown. The objective was to estimate the
net health benefit (NHB) of IM IFN--1a versus fingolimod. METHODS: A probabi-
listic Markov risk-benefit model was developed with three-month cycles and a
five-year time horizon (ten years in sensitivity analysis). Model inputs were ab-
stracted from the head-to-head trial, and incorporated intended (preventing pro-
gression and relapse) and serious unintended (cardiovascular events, serious in-
fections, and neoplasms) effects of treatment. Utilities for these were discounted at
5% annually, and combined using a minimum model. NHB was expressed in qual-
ity-adjusted life years (QALYs) per patient, with 95% credible intervals.RESULTS: In
a cohort of 1000 patients (mean age, 36 years), the NHB of treatment was 3.76
(3.30-4.08) QALYs with fingolimod and 3.73 (3.24-4.07) QALYs with IM IFN--1a over
five years. Fingolimod-treated patients accrued slightly more QALYs from intended
effects (3.88, vs. 3.82 QALYs for IM IFN--1a), but had higher QALY decrements from
unintended effects (-0.12, vs. -0.09 QALYs for IM IFN--1a). Findings were consis-
tent over a ten-year horizon. CONCLUSIONS: Even with greater relapse reduction
with fingolimod, both treatments have similar positive NHBs. This was driven by
similar disease progression rates between the treatments, and additional risks of
unintended effects with fingolimod. This model can assist clinicians and decision
makers in quantifying the trade-offs between intended and unintended treatment
effects, by jointly incorporating the benefits of slowing progression and reducing
relapses, with the risks of adverse events.
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OBJECTIVES: In the ALLEGRO Phase III clinical trial, 0.6 mg once daily laquinimod,
an oral treatment under development for the treatment of relapsing-remitting
multiple sclerosis (RRMS), showed a statistically significant 36% reduction in the
risk of confirmed disability progression according to the Expanded Disability Status
Scale (EDSS) versus placebo, in addition to a significant 23% reduction in the relapse
rate. The purpose of this analysis was to investigate health economic implications
of these efficacy results. METHODS: A computer model was developed to estimate
costs and health effects in the treatment of RRMS with laquinimod, allowing for
comparison against different treatment alternatives. The model used a 40-year
time horizon to capture long-term consequences, assuming that the treatment
duration would be 5 years in concordance with many other models in the field.
Efficacy data from the ALLEGRO trial and published cost and quality of life data for
Sweden were used to populate the model. As there is not yet an established market
price for laquinimod, the analysis focused on cost savings and gains in quality of
life. Costs and health effects were discounted at an interest rate of 3%. RESULTS:
Therapy with laquinimod during 5 years resulted in a gain of 0.29 quality adjusted
life years and societal cost offsets of EUR 58,000 over the modeled time period (0.11
Euro/Swedish Krona). On average, 0.5 relapses were also estimated to be avoided
during the treatment period. Over 40 years, patients spent 1.2 years less at EDSS
level 6 and above. The results were stable for reasonable variation of most model
parameters.CONCLUSIONS: Efficacy data from the ALLEGRO trial and Swedish cost
and quality of life data indicated potential cost savings and improved quality of life.
The most important driver of these results is the effect on disability progression.
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OBJECTIVES: To undertake a systematic benefit-risk analysis of glatiramer acetate
(GA) in relapse-remitting multiple sclerosis and clinical isolated syndrome using
controlled studies, according to the EMA guideline. METHODS: We searched
PubMed, Embase, the Cochrane Trials Register for eligible articles according to
explicit criteria to obtain trials and controlled cohort studies. Fixed and random
effects meta-analysis techniques were applied for pooling data. Qualitative and
quantitative benefit-risk analyses were performed. RESULTS: A total of 4451 pa-
tients in 15 studies were included in the meta-analysis. The overall reduction in
clinical progression was 40% (RR0.60, 95%CI: 0.48-0.75) for GA compared with
placebo/untreated and 23% (RR0.77, 95%CI: 0.65-0.92) for GA compared with in-
terferons. The rate of patients free from relapse was higher with GA compared with
placebo/standard treatment (RR1.35, 95%CI: 1.21-1.50) and similar compared with
interferons (RR1.04, 95%CI: 0.98-1.11). For GA compared with interferons there
was a13% reduction in discontinuation due to all causes (RR0.87, 95%CI: 0.72-1.04)
and a similar proportion of serious adverse events leading to discontinuation
(RR0.89, 95%CI: 0.56-1.41). Based on these results, for being free from disease
progression at 24 months against placebo/untreated, the number needed to benefit
was of 22.7 and the risk-benefit ratio was 1.69. Compared with placebo/untreated,
the relative net benefit-risk was 9% using a multi-criteria decision analysis.
A317V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
